Latest:

Fat Pitch Financials

Special situation stocks and value investing

Stock Quote

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Agenus Inc (NQ: AGEN )

1.840 -0.040 (-2.13%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 28, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,161,003
Open 1.880
Bid (Size) 1.840 (10)
Ask (Size) 1.960 (53)
Prev. Close 1.880
Today's Range 1.800 - 1.910
52wk Range 1.250 - 6.790
Shares Outstanding 270,990,987
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Agenus's Return On Capital Employed Insights
According to Benzinga Pro data, during Q1, Agenus (NASDAQ:AGEN) posted sales of $25.94 million. Earnings were up 25.15%, but Agenus still reported an overall loss of $50.60 million. 
Via Benzinga
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga

Performance

YTD
-46.97%
-46.97%
1 Month
+10.18%
+10.18%
3 Month
-34.05%
-34.05%
6 Month
-45.40%
-45.40%
1 Year
-66.05%
-66.05%

More News

Read More
Recap: Agenus Q1 Earnings
Via Benzinga
Looking Into Agenus's Return On Capital Employed
Via Benzinga
Recap: Agenus Q4 Earnings
Via Benzinga
Earnings Scheduled For March 1, 2022
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
Via Benzinga
68 Biggest Movers From Yesterday
Via Benzinga
41 Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 16, 2021
Via Benzinga
Agenus inc (AGEN) Q3 2021 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Agenus Posts Early Data For CTLA-4 Drug Candidate Across Tumor Types
Via Benzinga
Why Agenus Was Rising High on Tuesday
Via The Motley Fool
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
35 Stocks Moving In Friday's Mid-Day Session
Via Benzinga
The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data
Via Benzinga
Here's Why Agenus Stock Is Getting Hammered Today
Via The Motley Fool
55 Biggest Movers From Friday
Via Benzinga
Agenus' Combo Therapy Trial Shows Higher Responses In Cervical Cancer
Via Benzinga
The Daily Biotech Pulse: Lilly Strikes $1.6B R&D Collaboration, FSD Pulls Plug On COVID-19 Program, Cassava Sinks On Questions About Alzheimer's Drug
Via Benzinga
Exposures COVID-19
The Daily Biotech Pulse: Adcom Tryst For Pfizer/BioNTech Booster Shot, AbCellera's COVID Antibody Treatment Gets Expanded Use, Protagonist Slapped With Clinical Hold
Via Benzinga
The Daily Biotech Pulse: VectivBio In M&A Mix, Sonnet Biotherapeutics Advances Candidate To Clinics, CEO Transitions At Galapagos, Talis Biomedical
Via Benzinga
The Daily Biotech Pulse: MorphoSys-Incyte Snag European Nod, Immutep Granted Chinese Patent, Bolt Biotherapeutics Strike Oncology Collaboration
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
The Daily Biotech Pulse: Cara's Korsuva Greenlighted By FDA, Clinical Trial Disappointments For Novartis, Theravance, Vertex Inks CRISPR Licensing Deal
Via Benzinga
Exposures Product Safety
Stocks That Hit 52-Week Highs On Monday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.